Skip to main content
. 2006 Jun 27;1:19. doi: 10.1186/1748-717X-1-19

Table 1.

Results of surgery and stereotactic radiosurgery (SRS) for brain metastases

Reference n (patients and lesions) Prescribed dose (median; range [Gy])* Median OS 1-year PFS (%)
Patchell et al. 1990 [1] 25/25 Surgery 9.5 80
Patchell et al. 1998 [2] 49/49 Surgery 11.0 82
Pirzkall et al. 1998 [3] 236/311 20; 10–30 5.5 89
Cho et al. 1998 [4] 73/136 17.5; 6–50 7.8 80
Kocher et al. 1998 [5] 106/157 20; 12–25 8.0 85
Sneed et al. 1999 [6] 62/118a
43/117b
18; 15–22
17.5; 15–22
11.3
11.1
80
86
Varlotto et al. 2003 [7] 137/208 16; 12–25 Not given 90
Andrews et al. 2004 [8] 164/269c Not given; 15–24 6.5 82
Bhatnagar et al. 2006 [9] 205/4-18 lesions eachd 16; 12–20 8.0 71

OS: overall survival in months; PFS: progression-free survival; ?: data not reported

* Prescription isodose or point varied, some series included SRS plus WBRT

a SRS only

b SRS plus WBRT (no significant difference in OS and PFS between both groups)

c SRS plus WBRT

d SRS plus/minus WBRT